$9.33
-0.42-4.31%
Last update: Nov 5, 4:32 AM
Climb Bio Inc (CLYM) Stock Price, Quote, News & History
CLYMNASDAQ
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.
You can purchase shares of Climb Bio (NASDAQ:CLYM) through any online brokerage.
Other companies in Climb Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Climb Bio has a consensus price target of $24.79.
The stock price for Climb Bio (NASDAQ: CLYM) is $9.7 last updated November 5, 2026 at 4:32 AM EST.
There are no upcoming dividends for Climb Bio.
Climb Bio does not have any upcoming earnings scheduled.
There is no upcoming split for Climb Bio.
Climb Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases...
